The antibiotic combination has been approved for adults with cUTIs, including the kidney infection pyelonephritis, which is most commonly caused by gram-negative bacteria.
UTIs are a common infection and typically require antibiotics for treatment. Accounting for approximately 19% of all healthcare-associated infections, cUTIs have an increased likelihood of complications such as treatment failure and persistent or recurrent infection.
The FDA’s decision was supported by clinical data demonstrating Exblifep’s effectiveness against antimicrobial resistance (AMR) in gram-negative bacteria.
